Advanced gastric cancer has a poor prognosis; currently available palliative treatments result in survival of less than 18 months for most patients. Although immune checkpoint blockade has shown promise in chemorefractory gastric cancer, the modest benefit associated with anti-PD-1 therapy means that alternative gastric cancer vulnerabilities should continue to be explored.¹ Defective homologous recombination, classically found in BRCA-mutated tumours, has been successfully exploited by poly-ADP-ribose polymerase (PARP) inhibitors in ovarian, breast, and prostate cancer.

中文翻译：

---

错过胃癌的黄金机会

晚期胃癌预后较差；对于大多数患者而言，目前可用的姑息治疗导致不到18个月的生存期。尽管免疫检查点封锁已在化学难治性胃癌中显示出希望，但与抗PD-1治疗有关的适度获益意味着应继续探索替代性胃癌的脆弱性。¹缺陷同源重组通常在BRCA突变的肿瘤中发现，已被多ADP-核糖聚合酶（PARP）抑制剂成功地用于卵巢癌，乳腺癌和前列腺癌。